As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Aura Biosciences Inc. The largest reported stake is Chen Yu's, at 9.9%. 14 filings are on record since July 16, 2025 (Schedule 13G, May 12, 2026).
Sell to companies like Aura Biosciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 5,144,654 · Shared voting: 0 · Sole dispositive: 5,219,492 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-27
- · Reporting person: ForGrowth III PA B.V. · Sole voting: 0 · Shared voting: 5,248,841 · Sole dispositive: 0 · Shared dispositive: 5,248,841 · SCHEDULE 13G, 2026-10-01
- · Reporting person: Frazier Life Sciences Public Fund, L.P. · Sole voting: 0 · Shared voting: 5,807,260 · Sole dispositive: 0 · Shared dispositive: 5,807,260 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Long Focus Capital Management, LLC · Sole voting: 0 · Shared voting: 5,119,582 · Sole dispositive: 0 · Shared dispositive: 5,119,582 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Adage Capital Management, L.P. · Sole voting: 0 · Shared voting: 9,104,294 · Sole dispositive: 0 · Shared dispositive: 9,104,294 · SCHEDULE 13G/A, 2026-08-12
Aura Biosciences Inc has 14 Schedule 13D or 13G filings on record since 2025-07-16. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2026-08-11 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9.9% | 9,533,333 | SCHEDULE 13G, 2026-05-12 | 2026-05-05 | |
| Adage Capital Management, L.P. | 8.44% | 9,104,294 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Suvretta Capital Management, LLC | 7.6% | 4,701,775 | SCHEDULE 13G/A, 2025-08-13 | 2025-06-30 |
| Frazier Life Sciences Public Fund, L.P. | 5.6% | 5,807,260 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| ForGrowth III PA B.V. | 5.1% | 5,248,841 | SCHEDULE 13G, 2026-10-01 | 2026-09-25 |
| BlackRock, Inc. | 5.03% | 5,219,492 | SCHEDULE 13G, 2026-10-27 | 2026-09-30 |
| Long Focus Capital Management, LLC | 4.9% | 5,119,582 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Rajesh Parekh, Ph.D. | 3.34% | 2,071,857 | SCHEDULE 13G/A, 2026-02-17 | 2026-02-13 |
| Matrix Capital Management Company LP | 0% | 0 | SCHEDULE 13D/A, 2026-05-11 | 2026-05-07 |
Holding shares or following this stake? See who's behind Aura Biosciences Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Aura Biosciences Inc and the records around it.
Aura Biosciences Inc elsewhere on the record
- Leadership changes Aug 2026
- Layoff notices Aug 2026
- Who owns it
Companies that share a holder
- Matrix Capital Management Company LP also filed stake reports on 2 other companies: Zentalis Pharmaceuticals, Inc. (Jan 2026), Maze Therapeutics, Inc. (Nov 2025)
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Vor Biopharma Inc. (Dec 2025), Crescent Biopharma, Inc. (Dec 2025), Astria Therapeutics, Inc. (Nov 2025)
- LONG FOCUS CAPITAL MANAGEMENT, LLC also filed stake reports on 8 other companies: STANDARD BIOTOOLS INC. (Aug 2026), BICYCLE THERAPEUTICS PLC (May 2026), ONITY GROUP INC. (May 2026)
Watch Aura Biosciences Inc
Get an email when Aura Biosciences Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aura Biosciences Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aura Biosciences Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aura Biosciences Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Adage Capital Management, L.P. | 0 | 9,104,294 | 0 | 9,104,294 | SCHEDULE 13G/A, 2026-08-12 |
| Robert Atchinson | 0 | 9,104,294 | 0 | 9,104,294 | SCHEDULE 13G/A, 2026-08-12 |
| Phillip Gross | 0 | 9,104,294 | 0 | 9,104,294 | SCHEDULE 13G/A, 2026-08-12 |
| Frazier Life Sciences Public Fund, L.P. | 0 | 5,807,260 | 0 | 5,807,260 | SCHEDULE 13G/A, 2026-08-14 |
| Fhmlsp, L.P. | 0 | 5,807,260 | 0 | 5,807,260 | SCHEDULE 13G/A, 2026-08-14 |
| Fhmlsp, L.L.C. | 0 | 5,807,260 | 0 | 5,807,260 | SCHEDULE 13G/A, 2026-08-14 |
| Frazier Life Sciences X, L.P. | 0 | 128,520 | 0 | 128,520 | SCHEDULE 13G/A, 2026-08-14 |
| Fhmls X, L.P. | 0 | 128,520 | 0 | 128,520 | SCHEDULE 13G/A, 2026-08-14 |
| Fhmls X, L.L.C. | 0 | 128,520 | 0 | 128,520 | SCHEDULE 13G/A, 2026-08-14 |
| Frazier Life Sciences XI, L.P. | 0 | 358,810 | 0 | 358,810 | SCHEDULE 13G/A, 2026-08-14 |
| Fhmls Xi, L.P. | 0 | 358,810 | 0 | 358,810 | SCHEDULE 13G/A, 2026-08-14 |
| Fhmls Xi, L.L.C. | 0 | 358,810 | 0 | 358,810 | SCHEDULE 13G/A, 2026-08-14 |
| Frazier Life Sciences XII, L.P. | 0 | 805,410 | 0 | 805,410 | SCHEDULE 13G/A, 2026-08-14 |
| Fhmls Xii, L.P. | 0 | 805,410 | 0 | 805,410 | SCHEDULE 13G/A, 2026-08-14 |
| Fhmls Xii, L.L.C. | 0 | 805,410 | 0 | 805,410 | SCHEDULE 13G/A, 2026-08-14 |
| James N. Topper | 0 | 128,520 | 0 | 128,520 | SCHEDULE 13G/A, 2026-08-14 |
| Patrick J. Heron | 0 | 128,520 | 0 | 128,520 | SCHEDULE 13G/A, 2026-08-14 |
| ForGrowth III PA B.V. | 0 | 5,248,841 | 0 | 5,248,841 | SCHEDULE 13G, 2026-10-01 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 0 | 5,248,841 | 0 | 5,248,841 | SCHEDULE 13G, 2026-10-01 |
| Forbion Growth III Management B.V. | 0 | 5,248,841 | 0 | 5,248,841 | SCHEDULE 13G, 2026-10-01 |
| BlackRock, Inc. | 5,144,654 | 0 | 5,219,492 | 0 | SCHEDULE 13G, 2026-10-27 |
| Long Focus Capital Management, LLC | 0 | 5,119,582 | 0 | 5,119,582 | SCHEDULE 13G, 2026-08-14 |
| John Helmers | 0 | 5,119,582 | 0 | 5,119,582 | SCHEDULE 13G, 2026-08-14 |
The latest filing identifies Aura Biosciences Inc by CUSIP 05153U107 and gives its principal executive office as 80 GUEST STREET, BOSTON, MA 02135 (SCHEDULE 13G, 2026-10-27).
What the percentages are based on
The shares beneficially owned by the Reporting Persons represent approximately 5.1% of the outstanding Common Stock of the Issuer, based upon 103,704,809 shares outstanding as of August 6, 2026, as reported in the Issuer's Form 10-Q filed on August 11, 2026.ForGrowth III PA B.V., SCHEDULE 13G, 2026-10-01
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 4.9% | SCHEDULE 13G/A |
| 2025-08-13 | Suvretta Capital Management, LLC | 7.6% | SCHEDULE 13G/A |
| 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 5% | SCHEDULE 13G/A |
| 2025-10-17 | BlackRock, Inc. | 5.4% | SCHEDULE 13G |
| 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 6.3% | SCHEDULE 13G/A |
| 2026-02-17 | Rajesh Parekh, Ph.D. | 3.34% | SCHEDULE 13G/A |
| 2026-05-11 | Matrix Capital Management Company LP | 0% | SCHEDULE 13D/A |
| 2026-05-12 | Chen Yu | 9.9% | SCHEDULE 13G |
| 2026-07-27 | BlackRock, Inc. | 4.4% | SCHEDULE 13G/A |
| 2026-08-12 | Adage Capital Management, L.P. | 8.44% | SCHEDULE 13G/A |
| 2026-08-14 | Long Focus Capital Management, LLC | 4.9% | SCHEDULE 13G |
| 2026-08-14 | Frazier Life Sciences Public Fund, L.P. | 5.6% | SCHEDULE 13G/A |
| 2026-10-01 | ForGrowth III PA B.V. | 5.1% | SCHEDULE 13G |
| 2026-10-27 | BlackRock, Inc. | 5.03% | SCHEDULE 13G |
Questions about who owns Aura Biosciences Inc
Who owns Aura Biosciences Inc?
On this page, 6 holders' latest ownership filings report 5% or more of Aura Biosciences Inc: Chen Yu (9.9%, Schedule 13G, filed 2026-05-12), Adage Capital Management, L.P. (8.44%, Schedule 13G/A, filed 2026-08-12), Suvretta Capital Management, LLC (7.6%, Schedule 13G/A, filed 2025-08-13), Frazier Life Sciences Public Fund, L.P. (5.6%, Schedule 13G/A, filed 2026-08-14) and ForGrowth III PA B.V. (5.1%, Schedule 13G, filed 2026-10-01); 1 more is listed above.
Who are the largest shareholders of Aura Biosciences Inc?
By the share each holder's latest filing reports, the largest holders of Aura Biosciences Inc on this page are Chen Yu (9.9%), Adage Capital Management, L.P. (8.44%) and Suvretta Capital Management, LLC (7.6%).
When did Chen Yu buy into Aura Biosciences Inc?
The filings give report dates, not purchase dates. The earliest filing from Chen Yu on this page is the Schedule 13G, filed 2026-05-12, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Aura Biosciences Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 11, 2026 | Leadership change: Amy Elazzouzi appointed, Senior Vice President, Finance, and 1 more | — | Leadership changes | Source |
| July 8, 2026 | Leadership change: Jeremy Bender appointed, Director | — | Leadership changes | Source |
| May 4, 2026 | Leadership change: Natalie Holles appointed, Chief Executive Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Aura Biosciences Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.